Obermatt
See Similar Stocks →

GeneDx

NSQ:WGS · US81663L2007
Health Care Providers & ServicesMedium

360

6
EV / EBIT6
Price / Owner Earnings85
Owner Earnings Yield1
Dividend Yield1
Price/Sales37
EV / Gross Profit41
Price/Book31
Return on Capital12
Cash Return on Capital10
Return on Equity8
EBIT Margin15
Gross Profitability85
Accruals28
Owner Earnings Margin12
Sales growth56
Profit Growth21
Long-Term EPS Growth4
Owner Earnings Growth5
Reinvestment37
Price momentum47
Debt load43
Refinancing78
Debt Payback1
Liquidity13
Analyst ratings95
Opinion Changes50
Price Target Upside63
Market mood31
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

GeneDx doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Employees1,125
Websitesema4.com
ISINUS81663L2007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsMachine LearningGeneticsArtificial IntelligenceGenetic DisorderOncologyAnalyticsHealth CareMedicalPredictive Analytics

Description

GeneDx Holdings Corp. (GeneDx), through its subsidiary, GeneDx, LLC, operates as a genomics company. GeneDx Infinity GeneDx Infinity is powered by data from over 2.5 million tests – including over 1 million exomes and genomes – and supplemented wit…

Analysis

Weak and unloved

GeneDx Holdings Corp. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
36
2026

All-time high

60

Mar 2026

All-time low

36

Jun 2026

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
37
—
—
—
Price/Earnings
7
—
—
—
Price/Book
31
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
11
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare GeneDx with its peers
Intapp
NSQ:INTA
24
CountryUSA
IndustrySoftware
SizeMedium
Full Stock Analysis →
Upland Software
NMQ:UPLD
43
CountryUSA
IndustrySoftware
SizeSmall
Full Stock Analysis →
Salesforce
NYQ:CRM
73
CountryUSA
IndustrySoftware
SizeXX-Large
Full Stock Analysis →
Symbotic
NMQ:SYM
63
CountryUSA
IndustryMachinery
SizeLarge
Full Stock Analysis →
Viant Technology
NSQ:DSP
100
CountryUSA
IndustrySoftware
SizeSmall
Full Stock Analysis →
Braze
NSQ:BRZE
53
CountryUSA
IndustrySoftware
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →